Probiotic Chewables in Allergic Rhinoconjunctivitis Patients

Status Completed

Clinical Trial Summary

With this double- blind, randomised, placebo-controlled study, the investigators want to investigate the influence of a chewable with the probiotic strain Lacticaseibacillus rhamnosus GG on the symptoms and immunological markers of allergic rhinoconjunctivitis (AR). In addition, the investigators aim to study the influence of this probiotic chewable on the microbiome of the upper respiratory tract after administration in adults with AR. The bacterial and cytokine profiles in the naso- and oropharynx will be monitored before, during and after the treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04898686
Study type	Interventional
Source	University Hospital, Antwerp
Contact
Status	Completed
Phase	N/A
Start date	August 1, 2020
Completion date	August 6, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03850626` - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed	`NCT03682965` - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study	Phase 2
Completed	`NCT04541004` - Adolescent Mite Allergy Safety Evaluation	Phase 3
Completed	`NCT02556801` - Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy	Phase 2
Completed	`NCT01918956` - PURETHAL Birch RUSH Study	Phase 4
Completed	`NCT01966224` - A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects	Phase 1
Completed	`NCT01682070` - SUBLIVAC FIX Phleum Pratense DT/DRF	Phase 2
Completed	`NCT01438463` - PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis	Phase 2
Completed	`NCT01438827` - Avanz Phleum Pratense Maintenance Dose	Phase 2/Phase 3
Completed	`NCT02437786` - Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®	Phase 4
Completed	`NCT00985296` - Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)	N/A
Completed	`NCT01740284` - A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine	Phase 3
Completed	`NCT04912076` - S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen	Phase 1
Completed	`NCT03365648` - Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics	N/A
Completed	`NCT05455749` - Effect of holoBLG on Cat Allergic Patients	N/A
Completed	`NCT01707069` - A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid	Phase 1
Completed	`NCT01466465` - Vitamin D and Grass Pollen Specific Immunotherapy	Phase 2
Completed	`NCT01567306` - Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense	Phase 2
Completed	`NCT01490411` - Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis	Phase 2
Completed	`NCT00777374` - Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration	Phase 2